<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925117</url>
  </required_header>
  <id_info>
    <org_study_id>M16-048</org_study_id>
    <secondary_id>2016-002451-21</secondary_id>
    <nct_id>NCT02925117</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled
      multicenter study to evaluate the safety and efficacy of ABT-494 (upadacitinib) in adult
      subjects with moderate to severe atopic dermatitis. In Period 1, subjects will be randomized
      in a 1:1:1:1 ratio to one of four treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 25, 2016</start_date>
  <completion_date type="Anticipated">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">August 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage Change in EASI score</measure>
    <time_frame>At Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in EASI score</measure>
    <time_frame>From Day 1 (baseline) and Week 8</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving EASI 75 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving EASI 90 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving SCORAD 90 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving SCORAD 50 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of EASI 75 at all visits in Period 2 among those who were re-randomized as EASI 75 non-responders at Week 16</measure>
    <time_frame>Up to Week 88</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Dermatology Life Quality Index (DLQI) = &quot;0&quot; or &quot;1&quot;</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt;6 indicates that psoriasis has small or no effect at all on participant's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving SCORAD 75 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in SCORAD score</measure>
    <time_frame>From Day 1 to Week 16</time_frame>
    <description>The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of EASI 50 response relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16</measure>
    <time_frame>Up to Week 88</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from Week 16 (re-randomization) in EASI score at all Period 2 visits</measure>
    <time_frame>Up to Week 88</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving EASI 50 response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in pruritus/ itch numerical rating scale (NRS)</measure>
    <time_frame>From Day 1 (Baseline) to Week 16</time_frame>
    <description>Itch will be rated from 0 (no itch) to 10 (worst imaginable itch).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving an Investigator Global Assessment (IGA) of &quot;0&quot; or &quot;1&quot;</measure>
    <time_frame>At Week 16</time_frame>
    <description>The Investigators's Global Assessment (IGA) is a 5-point scale used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 (clear, no inflammatory signs of AD) to 4 (severe, Severe erythema and severe papulation/infiltration with or without oozing/crusting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in DLQI</measure>
    <time_frame>From Day 1 to Week 16</time_frame>
    <description>Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt;6 indicates that psoriasis has small or no effect at all on participant's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants achieving an EASI 75 response</measure>
    <time_frame>At Week 16</time_frame>
    <description>It is defined as at least a 75% reduction in EASI score relative to the baseline (day 1)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Participants receiving Dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Dose A once daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving Dose C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Dose C once daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receiving matching placebo for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving Dose B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Dose B once daily (QD) for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Participants receiving Dose A</arm_group_label>
    <arm_group_label>Participants receiving Dose B</arm_group_label>
    <arm_group_label>Participants receiving Dose C</arm_group_label>
    <other_name>Upadacitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Participants receiving matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the
             Hanifin and Rajka criteria) and onset of symptoms at least 1 year prior to baseline.

          -  Moderate to severe atopic dermatitis defined by an Eczema Area and Severity Index
             (EASI)&gt;= 16, Body Surface Area (BSA) &gt;= 10% and an Investigators Global Assessment
             (IGA) score &gt;= 3 at the Baseline visit.

          -  Documented history (within 1 year prior to the screening visit) of inadequate response
             to treatment with topical corticosteroids (TCS), or topical calcineurin inhibitors
             (TCI), or for whom topical treatments are otherwise medically inadvisable (e.g.,
             because of important side effects or safety risks).

          -  Twice daily use of an additive-free, bland emollient for at least 7 days prior to
             Baseline.

        Exclusion Criteria:

          -  Prior exposure to any systemic or topical JAK inhibitor (including but not limited to
             tofacitinib, baricitinib, ruxolitinib, and filgotinib).

          -  Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI),
             prescription moisturizers or moisturizers containing additives such as ceramide,
             hyaluronic acid, urea, or filaggrin within 10 days prior to the Baseline visit.

          -  Prior exposure to dupilumab.

          -  Prior exposure to any investigational systemic treatment within 30 days or 5
             half-lives (whichever is longer) of the Baseline visit or is currently enrolled in
             another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luis Derm and Laser Clinic</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Europaeisches Brusstzentrum</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermAssociates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Ctr NJ</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Med Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Rochester Med Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PL</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Connect Pty Ltd</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karma Clinical Trials</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Ottawa Research Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mikkeli Central Hospital</name>
      <address>
        <city>Mikkeli</city>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sairaala Neo</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Vaasa</name>
      <address>
        <city>Vaasa</city>
        <zip>65100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Klinikum Duesseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU Uniklinik Munchen</name>
      <address>
        <city>Munich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatological Clinic</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kojinkai S</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Med Ctr, St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Med Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Germans Trias I</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABT-494</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

